UnknownPhase 4

Cytotoxicity of Yellow Fever Specific CD8 T Cells Following YF-17D Vaccination

Denmark60 participantsStarted 2019-10-08

Plain-language summary

Investigating cytotoxicity of yellow fever specific CD8 T cells following YF-17D vaccination and the following licensing of these epitope-specific CD8 T cells

Who can participate

Age range18 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age between 18 to 60 years * Informed consent given Exclusion Criteria: * Fever (orally \>37,5 C) on day of vaccination * Immunosuppressants * Pregnant or breast feeding * Severe immunodeficiency * Known thymus dysfunction * Allergy against egg * Known haemophilia * Previous severe reaction to vaccine * Not willing to use anticonceptives 4 weeks after vaccination

What they're measuring

Incidence of cytotoxicity of the yellow fever specific (NS4B214LLWNGPMAV222) CD8 T cells 21(+/-3) days after vaccination with YF-17D

Timeframe: 21(+/-3) days

Incidence of cytotoxicity of the yellow fever specific (NS4B214LLWNGPMAV222) CD8 T cells 100 (+/- 40) days after vaccination with YF-17D

Timeframe: 100 (+/- 40) days

Trial details

NCT IDNCT04083430

SponsorUniversity of Aarhus

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-02-15

View on ClinicalTrials.gov More Healthy trials